Henan Taloph Pharmaceutical Stock Co.,Ltd (SHA:600222)
7.28
-0.15 (-2.02%)
Mar 11, 2026, 11:24 AM CST
SHA:600222 Revenue
Henan Taloph Pharmaceutical Stock Co.,Ltd had revenue of 424.47M CNY in the quarter ending September 30, 2025, with 2.67% growth. This brings the company's revenue in the last twelve months to 1.79B, down -9.15% year-over-year. In the year 2024, Henan Taloph Pharmaceutical Stock Co.,Ltd had annual revenue of 1.94B, down -6.21%.
Revenue (ttm)
1.79B
Revenue Growth
-9.15%
P/S Ratio
2.30
Revenue / Employee
807.43K
Employees
2,214
Market Cap
4.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.94B | -128.49M | -6.21% |
| Dec 31, 2023 | 2.07B | 109.21M | 5.57% |
| Dec 31, 2022 | 1.96B | 356.18M | 22.20% |
| Dec 31, 2021 | 1.60B | 187.42M | 13.23% |
| Dec 31, 2020 | 1.42B | 105.28M | 8.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Starry Pharmaceutical | 2.39B |
| PKU HealthCare Corp.,Ltd. | 1.76B |
| Huaren Pharmaceutical | 1.26B |
| LanZhou Foci Pharmaceutical | 895.75M |
| Shandong Wohua Pharmaceutical | 816.95M |
| Qianjiang Yongan Pharmaceutical | 797.25M |
| Tibet AIM Pharm. | 628.02M |
| Wuhan Hiteck Biological Pharma Co.,Ltd | 619.88M |